Skip to main content
. 2016 Apr 28;13(6):5045–5052. doi: 10.3892/mmr.2016.5204

Figure 2.

Figure 2

Combined TSA and genistein treatment prevents EGF-induced HEp-2 cell epithelial-mesenchymal transition and invasion. HEp-2 cells were treated with EGF in the presence or absence of TSA, genistein or TSA+genistein for 48 h, and (A) corresponding cell morphological changes were recorded. Green arrows indicate apoptotic cells and red arrows indicate migrating cells. Magnification, ×400. (B) Expression levels of E-caderin and vimentin were detected using western blotting. (C) Cell invasive ability was examined using a Transwell-based invasion assay. (D) HEp-2 cells were treated with EGF in the presence of absence of TSA, genistein or TSA+genistein for 24 h, and a scratch wound migration assay was performed. The data are summarized from three independent experiments and are expressed as the mean ± standard error of the mean. *P<0.05, **P<0.01 and ***P<0.001, vs. Mock. TSA, trichostatin A; EGF, epidermal growth factor.